Holen Sie sich die Stockscreener-App
3.42
6.04%
-0.22
Handel nachbörslich:
3.40
-0.02
-0.58%
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
Why ImmunityBio (IBRX) Is Surging Today - MSN
ImmunityBio stock gains 15% amid regulatory updates - MSN
ImmunityBio cleared to bring alternative BCG treatment source amid Merck shortage - MSN
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer - Yahoo
FDA approves expanded access for ImmunityBio's bladder cancer drug By Investing.com - Investing.com South Africa
Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday? - Yahoo Finance
Sector Update: Health Care Stocks Advance Late Afternoon - TradingView
Sector Update: Health Care -February 19, 2025 at 03:41 pm EST - Marketscreener.com
ImmunityBio stock gains as FDA clears Merck rival (IBRX:NASDAQ) - Seeking Alpha
FDA Authorizes Immunitybio To Provide Rbcg To Urologists -February 19, 2025 at 10:16 am EST - Marketscreener.com
Why ImmunityBio’s Stock is Gaining Attention - TipRanks
FDA Authorizes ImmunityBio To Provide Recombinant Bcg (Rbcg) To Urologists To Address Tice® Bcg Shortage - Marketscreener.com
ImmunityBio Gets FDA Authorization for Expanded Access to Recombinant BCG for Bladder Cancer Treatment - Marketscreener.com
FDA approves expanded access for ImmunityBio's bladder cancer drug - Investing.com
Critical BCG Shortage Solution: FDA Grants Access to New Treatment SourceWhat Urologists Should Know - StockTitan
FDA Allows Use of Recombinant BCG Through Expanded Access Program - Monthly Prescribing Reference
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins - Baystreet.ca
ImmunityBio (NASDAQ:IBRX) Trading 12.6% HigherStill a Buy? - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio's Application for Anktiva Approved for Review in UK -February 13, 2025 at 03:38 pm EST - Marketscreener.com
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
ImmunityBio announces executive compensation updates By Investing.com - Investing.com Canada
ImmunityBio announces executive compensation updates - MSN
ImmunityBio Approves 2024 Executive Bonuses and New Incentives - TipRanks
Major Regulatory Win: ImmunityBio's Cancer Drug ANKTIVA Advances in UK After US Success - StockTitan
Why Immunitybio Inc. (IBRX) Soared on Thursday - MSN
Natural Killer Cell Therapies Clinical and Non-Clinical - openPR
ImmunityBio (NASDAQ:IBRX) Shares Down 6.8%Time to Sell? - MarketBeat
ImmunityBio board member John Brennan resigns - MSN
ImmunityBio board member John Brennan resigns By Investing.com - Investing.com South Africa
IBRX 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm’s Attorneys Before Aug. 29th Deadline in Securities Fraud Class Action - ACCESS Newswire
ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Update - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Down 6.8%Should You Sell? - MarketBeat
BTIG Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation - MSN
ImmunityBio (NASDAQ:IBRX) Shares Up 17.2%Time to Buy? - MarketBeat
ImmunityBio and BeiGene ink research collaboration - The Pharma Letter
D. Boral Capital Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio Continues Trimming Workforce While Working to Advance Anktiva - BioSpace
Here’s Why ImmunityBio, Inc. (IBRX) Will Double in 2025 - Insider Monkey
ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo - Yahoo Finance
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism - MSN
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene - MarketWatch
Why ImmunityBio Stock is Gaining Momentum - TipRanks
ImmunityBio Partners With BeiGene to Conduct Phase 3 Trial of Lung Cancer Combination Therapy - Marketscreener.com
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire
ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from D. Boral Capital - MarketBeat
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):